Fidelity International’s Aprea Therapeutics APRE Stock Holding History

Fidelity International’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,160	Closed	-$406K	–	825
2021 Q2	$406K	Hold	4,160	–	–	﹤0.01%	794
2021 Q1	$424K	Buy	4,160 +4,136	+17,233%	+$483K	﹤0.01%	769
2020 Q4	$2K	Buy	24 +9	+60%	+$4.28K	﹤0.01%	823
2020 Q3	$7K	Buy	+15	New	+$8.39K	﹤0.01%	766

Other funds holding APRE

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity International's APRE Position: Q3 2021 in Review

Fidelity International sold out of Aprea Therapeutics (APRE) in Q3 2021, closing a stake of 4,160 shares — an estimated $406K sold.

Fidelity International first reported a position in APRE in Q3 2020 and held it in 4 quarters. The position peaked at $424K in Q1 2021. 39 funds tracked by Wall St. Rank hold APRE as of Q3 2021.

Fidelity International reported no remaining Aprea Therapeutics position as of Q3 2021 after selling out during the quarter.
Fidelity International sold 4,160 Aprea Therapeutics shares in Q3 2021, an estimated $406K.
Fidelity International first reported a position in Aprea Therapeutics in Q3 2020 and held it in 4 quarters.
Fidelity International's Aprea Therapeutics position peaked at $424K in Q1 2021.
39 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2021.

Based on Fidelity International's 13F filing for Q3 2021, filed 15 Nov 2021.